{"id":512008,"date":"2021-07-12T16:13:17","date_gmt":"2021-07-12T20:13:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/"},"modified":"2021-07-12T16:13:17","modified_gmt":"2021-07-12T20:13:17","slug":"arcus-biosciences-announces-new-employment-inducement-grants-9","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/","title":{"rendered":"Arcus Biosciences Announces New Employment Inducement Grants"},"content":{"rendered":"

<\/p>\n

Arcus Biosciences Announces New Employment Inducement Grants<\/b><\/p>\n

HAYWARD, Calif.–(BUSINESS WIRE<\/a>)–
\nArcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company\u2019s Board of Directors granted seven new employees options to purchase a total of 77,800 shares of the Company\u2019s common stock at an exercise price per share of $28.75, which was the closing price on July 8, 2021. The stock options were granted pursuant to the Company\u2019s 2020 Inducement Plan, which was approved by the Company\u2019s Board of Directors in January 2020 pursuant to the \u201cinducement exception\u201d under NYSE Listed Company Manual Rule 303A.08.\n<\/p>\n

About Arcus Biosciences<\/b><\/p>\n

\nArcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has five molecules in clinical development: Etrumadenant (AB928)<\/b>, the first dual A2a<\/sub>\/A2b <\/sub>adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, and pancreatic cancers. AB680<\/b>, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1\/1b development in combination with zimberelimab and gemcitabine\/nab-paclitaxel for first-line treatment of metastatic pancreatic cancer. Domvanalimab (AB154) <\/b>is an Fc-silent anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy. In addition to ARC-7, domvanalimab is being investigated in a registrational, Phase 3 study, ARC-10, a \u201ctwo in one trial\u201d to support the potential approvals of both zimberelimab alone and domvanalimab plus zimberelimab compared to chemotherapy in first-line locally advanced or metastatic, PD-L1>50% NSCLC. An additional registrational Phase 3 study is being planned in collaboration with AstraZeneca in earlier disease with curative intent. AB308<\/b>, an anti-TIGIT antibody that is Fc-enabled, is in clinical development, with a potential focus on hematological malignancies. Zimberelimab (AB122)<\/b>, Arcus\u2019s anti-PD-1 monoclonal antibody, is being evaluated in various combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com<\/a>.\n<\/p>\n

\nInducement PR\n<\/p>\n

\nSource: Arcus Biosciences\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210712005708\/en\/<\/a><\/span><\/p>\n

\nKatherine Bock
\n
VP Investor Relations & Corporate Strategy
\n
(510) 694-6231
\n
kbock@arcusbio.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Clinical Trials Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Arcus Biosciences Announces New Employment Inducement Grants HAYWARD, Calif.–(BUSINESS WIRE)– Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company\u2019s Board of Directors granted seven new employees options to purchase a total of 77,800 shares of the Company\u2019s common stock at an exercise price per share of $28.75, which was the closing price on July 8, 2021. The stock options were granted pursuant to the Company\u2019s 2020 Inducement Plan, which was approved by the Company\u2019s Board of Directors in January 2020 pursuant to the \u201cinducement exception\u201d under NYSE Listed Company Manual Rule 303A.08. About Arcus Biosciences Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary … <\/p>\n

Continue reading “Arcus Biosciences Announces New Employment Inducement Grants”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-512008","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nArcus Biosciences Announces New Employment Inducement Grants - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcus Biosciences Announces New Employment Inducement Grants - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Arcus Biosciences Announces New Employment Inducement Grants HAYWARD, Calif.–(BUSINESS WIRE)– Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company\u2019s Board of Directors granted seven new employees options to purchase a total of 77,800 shares of the Company\u2019s common stock at an exercise price per share of $28.75, which was the closing price on July 8, 2021. The stock options were granted pursuant to the Company\u2019s 2020 Inducement Plan, which was approved by the Company\u2019s Board of Directors in January 2020 pursuant to the \u201cinducement exception\u201d under NYSE Listed Company Manual Rule 303A.08. About Arcus Biosciences Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary … Continue reading "Arcus Biosciences Announces New Employment Inducement Grants"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-12T20:13:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210712005708r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-announces-new-employment-inducement-grants-9\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-announces-new-employment-inducement-grants-9\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arcus Biosciences Announces New Employment Inducement Grants\",\"datePublished\":\"2021-07-12T20:13:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-announces-new-employment-inducement-grants-9\\\/\"},\"wordCount\":389,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-announces-new-employment-inducement-grants-9\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210712005708r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-announces-new-employment-inducement-grants-9\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-announces-new-employment-inducement-grants-9\\\/\",\"name\":\"Arcus Biosciences Announces New Employment Inducement Grants - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-announces-new-employment-inducement-grants-9\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-announces-new-employment-inducement-grants-9\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210712005708r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-07-12T20:13:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-announces-new-employment-inducement-grants-9\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-announces-new-employment-inducement-grants-9\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-announces-new-employment-inducement-grants-9\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210712005708r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210712005708r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcus-biosciences-announces-new-employment-inducement-grants-9\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcus Biosciences Announces New Employment Inducement Grants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arcus Biosciences Announces New Employment Inducement Grants - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/","og_locale":"en_US","og_type":"article","og_title":"Arcus Biosciences Announces New Employment Inducement Grants - Market Newsdesk","og_description":"Arcus Biosciences Announces New Employment Inducement Grants HAYWARD, Calif.–(BUSINESS WIRE)– Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company\u2019s Board of Directors granted seven new employees options to purchase a total of 77,800 shares of the Company\u2019s common stock at an exercise price per share of $28.75, which was the closing price on July 8, 2021. The stock options were granted pursuant to the Company\u2019s 2020 Inducement Plan, which was approved by the Company\u2019s Board of Directors in January 2020 pursuant to the \u201cinducement exception\u201d under NYSE Listed Company Manual Rule 303A.08. About Arcus Biosciences Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary … Continue reading \"Arcus Biosciences Announces New Employment Inducement Grants\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-12T20:13:17+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210712005708r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arcus Biosciences Announces New Employment Inducement Grants","datePublished":"2021-07-12T20:13:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/"},"wordCount":389,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210712005708r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/","name":"Arcus Biosciences Announces New Employment Inducement Grants - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210712005708r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-07-12T20:13:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210712005708r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210712005708r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcus-biosciences-announces-new-employment-inducement-grants-9\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arcus Biosciences Announces New Employment Inducement Grants"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/512008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=512008"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/512008\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=512008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=512008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=512008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}